Background/Aims: Numerous studies have suggested that the promoter methylation status of O6-methylguanine-DNA methyltransferase (MGMT) is significantly associated with breast cancer. However, these studies have not demonstrated consistent results. Methods: To obtain more accurate results for this possible association, we performed a meta-analysis-based study using the relevant data. A total of 14 articles were included in this meta-analysis. Results: Our study showed that the frequency of MGMT promoter methylation was significantly higher in patients with breast cancer than non-breast cancer subjects with an Odds Ratio (OR) of 4.47, a 95% Confidence Interval (CI) ranging between 1.95 -10.25 and a P value of 0.0004. Moreover, MGMT methylation was significantly associated with the negative expression of the MGMT protein (OR = 4.65, 95%CI = 2.66 -8.12, P < 0.00001), Oestrogen Receptor (ER)-negative tumours (OR = 1.79, 95%CI = 1.09 -2.93, P = 0.02), postmenopausal status (OR =1.84, 95%CI = 1.18 -2.87, P = 0.007) and histological grade III tumours (OR = 2.49, 95%CI = 1.53 -4.07, P = 0.0003) in breast cancer patients. However, breast cancer was not significantly correlated with lymph node metastasis (OR = 1.19, 95%CI = 0.83 -1.70, P = 0.35), Progesterone Receptor (PR) status (OR = 1.08, 95%CI = 0.58 -2.00, P = 0.81), Human epidermal growth factor receptor -2（HER-2/neu）status (OR = 1.01, 95%CI = 0.65 -1.57, P = 0.97), P53 mutation (OR = 1.30, 95%CI = 0.76 -2.21, P = 0.34) and age > 50 (OR = 1.07, 95%CI = 0.46 -2.51, P = 0.88). Conclusions: Our study suggests that MGMT promoter methylation may be an early biomarker for the diagnosis of breast cancer.
Introduction
Cancer is a type of malignant tumour that originates in the epithelial tissue. Cancer may be the synthetic result of acquired inheritance in somatic cells, the genome and epigenetic alterations in cancer cells [1] . Breast cancer is the most common type of cancer in women and the primary cause of death among women worldwide [2] [3] [4] [5] [6] . The pathogenesis of breast cancer is still not clear; however, advances in molecular biology have led more researchers to study the epigenetics of breast cancer. Esteller et al. provided evidence to strongly support epigenetic mechanisms, including the methylation of cytosines in DNA, changes in histone and chromatin structure due to the covalent posttranslational modifications of histone proteins and alterations in the expression of microRNAs in the progression of breast tumourigenesis [7, 8] . The alterations in epigenetics, particularly in the methylation status of the CpG islands of DNA promoter regions, were considered as early events in cancer [9] , which play crucial roles in tumour progression and may serve as biomarkers for cancer diagnosis [10] [11] [12] . DNA methylation in mammals occurs at carbon-5 of the cytosine residues of cytosine-phosphatidyl-guanosine (CpG) dinucleotides [12] . DNA methylation fulfils the essential requirements of epigenetic cyphers by stably regulating gene expression and maintaining the mechanism of these expression patterns through mitosis [13] . Mitosis can sufficiently account for the gene expression of these specific patterns from imprinting X-inactivation to germ cell-restricted gene expression observed in mature organisms [14] . Notably, increasing evidence suggests that the regulation of DNA methylation patterns involves microRNAs. Sun et al. found that miR-361-5p was significantly down regulated in hepatocellular carcinoma tissues due to epigenetic mechanisms involving DNA methylation [15] . A study by Teng et al. has shown that the transcriptional silencing of miR-29b in epithelial ovarian cancer cells is associated with the hypermethylation of CpG islands [16] . MGMT, located on chromosome 10q26, is a DNA repair gene that encodes the DNA-repair protein O 6 -alkylguanine (O 6 -AG) DNA alkyl transferase (AGT) [17] , which transfers the alkyl group from the O6 position of guanine in DNA to a cysteine residue of its active site [4, [17] [18] [19] [20] [21] . If the alkyl group is not removed, the interchain cross-links formed by O6-alkyl guanine would inhibit DNA replication and cause the incorporation of incorrect base pairs [4] . Moreover, O6-methylguanine has the tendency to pair with thymine during replication [22] and trigger the conversion of G-to-A during base-pairing, causing mutations together with other factors. The MGMT protein restores guanine and inactivates itself during the process [4] , providing to the cell a significant defence mechanism against tumourigenesis [23] . MGMT methylation has been reported to occur in one-third of all breast cancers, irrespective of the hormone receptors and Her-2 status [24] . Currently, the study of MGMT methylation is no longer confined to tumour tissues. Spitzwieser et al. tested the applicability of the MGMT promoter methylation as biomarkers in breast cancer tissues, tumour-adjacent and tumour-distant tissues [12] , Taback et al. used bone marrow (BM) aspirates and paired serum samples [25] and Sharma et al. used the serum of breast cancer patients [22] to detect MGMT methylation. These studies concluded that the percentages of MGMT promoter methylation were different among tumour tissues, paired adjacent normal tissues and peripheral blood derived from the breasts cancers of healthy women. Recently, many researchers have studied the association between MGMT promoter methylation and breast cancer risk or its clinicopathological features. Perhaps, small samples or errors existed among different studies due to which the percentage of MGMT methylation as well as its association with clinicopathological features or breast cancer risk were not always consistent. To obtain more reliable and systematic results, we performed a meta-analysis to implicate MGMT gene promoter methylation as a risk factor for breast cancer and study its association with clinicopathological features.
Materials and Methods

Search Strategy
Two independent retrievers (Nairui An and Yu Shi) searched and obtained information from previously published studies. All articles contained in this meta-analysis are from PubMed, CNKI and EMBASE databases and date up to April 2017. The keywords used to carry out this search were: 'MGMT' or 'O6-methylguanine-DNA methyltransferase', 'DNA methylation' or 'methylation' or 'promoter methylation' and 'breast cancer' or 'breast tumour' or 'breast carcinoma'. 
Literature Screening and Data Extraction
The literature was strictly selected according to the inclusion and exclusion criteria. Nairui An, Peng Ye and Zhongya Pan extracted data independently from qualified articles, and any inconsistencies were resolved by consensus. A standard protocol was applied to extract data, which were retrieved from qualified studies including the surname of the first author, the year of publication, country, specimen type, methylation quantitative detection methods, the number of MGMT gene promoter methylation and unmethylation in the case group and the control group, as well as controls and cases characteristics.
Statistical Analysis
RevMan5.3 Software from Cochrane Collaboration and STATA 13.1 were used for statistical analysis. OR and its corresponding 95%CI were used for quantifying the association between MGMT gene promoter methylation and breast cancer risk or clinicopathological characteristics. The heterogeneity among the included studies was verified by the χ2 test based on Q -test. P value ≥ 0.10 and I 2 ≤ 50% indicated that the literature was homogeneous. The fixed effect model (Mantel-Haenszel) [26] was used for this meta-analysis. Similarly, P < 0.10 or I 2 > 50% indicated the existence of heterogeneity among literature, and the Random effect model (DerSimonian Laird) [27] was used. The I 2 value from the χ2 test was used to represent the degree of heterogeneity. It is believed that there is no heterogeneity if I 2 is in the range from 0% to 25% while the range from 25% to 50% shows moderate heterogeneity. Moreover, the range from 50% to 75% indicates large heterogeneity and the range from 75% to 100% implies extremely large heterogeneity [28] . A sensitivity analysis was performed to observe the stability of the results by deleting one study at each time in our meta-analysis. We used funnel plots and Egger's linear regression to evaluate the publication bias of the included literature. If the funnel plot is visually symmetric and the P value from the Egger's test is greater than 0.05, there is no statistically apparent publication bias. All statistical tests were bilateral in our meta-analysis. The consolidated ORs were based on the Z-test, and a P value of less than 0.05 was considered to be statistically significant unless otherwise stated.
Results
Qualified Study Characteristics
According to the retrieval scheme of this study, we initially obtained 178 articles. Ultimately, 14 articles [4, 12, [22] [23] [24] [25] [29] [30] [31] [32] [33] [34] [35] and Fu [2009] (unpublished data) met the inclusion and exclusion criteria of our meta-analysis. The flow chart of the specific screening process is shown in Fig. 1 . Notably, one study [22] examined the methylation of MGMT promoter in breast cancer and normal tissues and paired serum and serum from healthy female participants. Because of different study materials, we considered them as two separate case-control studies. Therefore, 15 studies overall were involved in our meta-analysis. Ten studies [12, 22, 25, 29-32, 34, 35] 
837 cases and 380 controls elucidated the association between MGMT methylation and the breast cancer risk. Ten studies from 9 articles [4, 22-24, 29, 31, 33-35] analysed the association of MGMT promoter methylation with the clinicopathological features of breast cancer. The characteristics of these studies, included in the control and case groups, are shown in Table 1 and Table 2 , respectively.
The Results of the Meta-analysis
Association of MGMT promoter methylation with breast cancer risk. Our results showed that the frequency of MGMT promoter methylation in the breast cancer groups was significantly higher than in the non-breast cancer groups (OR = 4.47, 95%CI = 1.95 -10.25, P = 0.0004), as shown in Fig. 2 . Because of the existence of heterogeneity (P = 0.03, I 2 = 50%) in our results, we performed a subgroup analysis based on the retrieved sample materials and methylation detection methods to find the potential sources of heterogeneity. The subsequent detailed results of the stratification analysis are summarized in Table 3 . The consolidated OR using MSP was 5.81 (95%CI = 1.43 -23.54, P = 0.01), which was significantly higher than the others (OR = 3.05, 95%CI = 1.15 -8.08, P = 0.02) in the subgroup analysis, classified by methylation assay methods. Furthermore, the consolidated OR of the breast cancer patients compared with healthy women or benign female participants was 4.57 (95%CI = 1.56 -13.43, P = 0.006)in tissues. The results of the subgroup analysis are shown in Table 3 .
Association of MGMT promoter methylation with clinicopathological characteristics of breast cancer
Our results suggested that MGMT promoter methylation was significantly associated with the negative expression of the MGMT protein (OR = 4.65, 95%CI = 2.66 -8.12, P<0.00001), postmenopausal status (OR = 1.84, 95%CI = 1.18 -2.87, P = 0.007), ER-negative tumours (OR = 1.79, 95%CI = 1.09 -2.93, P = 0.02) and histological grade III tumours (OR = 2.49, 95%CI =1.53 -4.07, P = 0.0003) in breast cancer, as shown in Figures 3, 4, 5 and 6 . Similarly, as shown in Table 4 , MGMT promoter methylation was not significantly associated 
Sensitivity analysis and publication bias assessment
We used Begg's funnel plot and Egger's linear regression test by STATA 13.1 software to evaluate the publication bias of the included studies. The funnel plot (Fig. 7) showed the basic symmetrical distribution of literature and the P value of Egger's linear regression test (p = 0.783, Table 3 ) was greater than 0.05, indicating that there was no publication bias in the study on the association of MGMT promoter methylation with the risk of breast cancer. The P values of Egger's linear regression test for the association between MGMT promoter methylation and clinicopathological features of breast cancer are shown in Table 4 . Only the P value for the negative expression of the MGMT protein (P = 0.008) was less than 0.05, suggesting a small publication bias in the study. Moreover, the P values for Egger's linear regression test for subgroup analysis were all greater than 0.05 (Table 3) , showing the absence of a publication bias. Sensitivity analysis (Fig. 8 ) was conducted by ignoring individual studies to examine the change in the integration outcome. Sensitivity analysis in our meta-analysis showed that the results were stable with no significant changes in the omission of individual studies.
Discussion
Although the specific pathogenesis of breast cancer, a major malignant disease threatening women's health globally in recent years, is not yet clear, it is undeniable that abnormal DNA methylation is an important molecular mechanism in tumour formation. MGMT is located on the chromosome 10q26 and plays a key role in DNA repair. Our comprehensive survey included 10 studies with 837 cases and 380 controls to explore the association between MGMT promoter methylation and the risk of breast cancer. Our results showed that the methylation of the MGMT promoter in the breast cancer group was 4.47 times higher than that in the non-breast cancer group, which further illustrated a statistically significant association. Moreover, our study verified that MGMT methylation was significantly related to the negative expression of the MGMT protein, ER-negative tumours, postmenopausal status and histological grade III tumours in breast cancer. Our research suggested that the methylation of the MGMT promoter may be a potential biomarker for the diagnosis of breast cancer. The abundance of genes in cancer tissues, abnormalities in the early stages of cancer formation, the relative stability of methylated biomarkers and the easily detectable changes in serum, sputum, or minimally invasive surgery facilitate the use of monitoring sequences containing DNA promoter hypermethylation of CpG islands as a diagnostic tool in cancer [36] . The methylation of the MGMT promoter could be a powerful, potential biomarker in the clinical diagnosis and prognosis of breast cancer. Our study demonstrated a significantly strong association between the frequency of MGMT gene promoter methylation and the risk of breast cancer，indicating that the abnormal methylation of the MGMT promoter would elevate the risk of breast cancer. In the subgroup analysis grouped with sample materials, our data showed that the combined OR in tissues (OR = 4.57) was higher than in blood samples (OR = 3.78), indicating a higher risk of breast cancer in tissues. Notably, DNA can be easily extracted from serum or plasma with small trauma. It is more interesting to extract DNA from bone marrow aspirates [25] . Thus, these studies are innovative in the diagnosis of breast cancer. Furthermore, there were 5 studies in the MSP groups (OR = 5.81) and 5 studies in Others (OR = 3.05) in the subgroup analysis based on MGMT methylation detection methods. Accordingly, different methods of MGMT methylation detection may affect the early diagnosis of breast cancer, and it is important to select the appropriate methods that can be used to guide clinical practices.
In recent decades, the studies on the inverse relationship between the MGMT promoter methylation and MGMT protein negative expression have been increasing in epigenetics. Our findings were consistent with the results of Asiaf (rs = − 0.285, p < 0.05) [29] and Sharma (p = 0.002, OR = 4.5, 95%CI = 1.7 -12.0) [22] that the MGMT promoter methylation was significantly associated with the negative expression of the MGMT protein. Thus, MGMT promoter methylation was not associated with breast cancer patients who were over 50 years of age in our study. However, Tserga et al. believed that MGMT methylation was more often observed in older patients (Mann-Whitney U test, p = 0.0222) [23] . When we extracted the age data related to the MGMT promoter methylation, we classified the breast cancer patients > 50 years of age into the experimental group and ≤ 50 years old into the control group. Unexpectedly, patients ≥ 50 years old were divided into the same groups as in the two studies by Fu [35] and Fumagalli [24] . We speculated that the threshold of age caused this difference; thus, further studies are needed to demonstrate the association between MGMT methylation and age. Our results showed that MGMT promoter methylation had an enhanced association with the ER-negative tumours, indicating that such breast tumours rarely benefit from traditional hormone therapy. However, MGMT methylation was not associated with the PR status or the Her2 and P53 status. Similarly, our comprehensive survey showed that the MGMT promoter methylation was not significantly associated with the lymph node metastasis in breast cancer. Interestingly, we found that the MGMT promoter methylation was significantly associated with the postmenopausal status, suggesting an increase in the risk of breast cancer in older women. Moreover, our meta-analysis showed that the association between the MGMT promoter methylation and the histological grade III tumours was more significant in the breast cancer group compared with the control group.
Although our study used a rational design and good procedure implementation, there were some limitations. First, this meta-analysis was a comprehensive investigation on the basis of case-control studies, which may have a selection bias of literature. Second, our results did not consistently show an association between the frequency of MGMT promoter methylation and the risk of breast cancer. We used subgroup analysis and regression analysis to determine the sources of heterogeneity in our results. Our results showed that sample materials and methylation detection methods were not significant factors in causing heterogeneity. However, from a professional perspective, the differences in methods and materials may cause heterogeneity among studies, pending further studies based on the exploration of large samples. We also did a sensitivity analysis by eliminating the studies one by one but did not identify the factors that could significantly affect heterogeneity. Third, to a certain extent, the absence of a clear definition of a control group affected the results of our study. Furthermore, since this study was an analysis based on the original data from relevant studies, it was not possible to correct the confounding factors in the original data such as age, race, and sex. Finally, the lack of original data from the existing research limited our further assessment of the potential association between MGMT methylation and breast cancer.
Conclusion
Our study suggested that the methylation of the MGMT promoter was significantly associated with the risk of breast cancer and several clinicopathological features. Compared with patients with breast cancer, the prevalence of MGMT methylation in healthy women or benign female patients was significantly lower. The prevalence of MGMT methylation was closely associated with the negative expression of the MGMT protein, ER-negative tumours, postmenopausal status and histological grade III tumours in breast cancer patients. The detection of MGMT methylation might provide a highly specific and sensitive molecular substitute for diagnosis and clinical management of breast cancer. However, studies based on large samples and well-defined control groups are necessary before MGMT is deemed a biomarker for the diagnosis and prognosis of breast cancer.
